Accelerating Drug Discovery: Computational Drug Repurposing of IGURATIMOD From Delta4

Delta4’s mission centers on leveraging the synergy of artificial intelligence (AI) and data-driven network analysis to uncover new therapeutic indications for drugs with established safety profiles. This approach utilizes their proprietary software platform, HyperC.

Using AI to Discover New Indications for Drugs with Known Safety Profiles

A recent whitepaper released by Delta4 highlights their work with Iguratimod, a drug initially developed for rheumatic conditions. Iguratimod’s broad anti-inflammatory and anti-fibrotic effects have attracted scientific interest beyond its original uses. Through meticulous analysis facilitated by HyperC, Delta4 has uncovered novel disease-drug relationships for Iguratimod, expanding its potential applications significantly. The process involves a thorough examination of the drug’s background, molecular targets, and mechanisms of action, seamlessly integrated into the HyperC platform.

Watch the video below to learn more how Delta4 used HyperC in their work with Iguratimod.

What is Hyper-C?

Hyper-C represents a groundbreaking in-silico platform equipped with advanced algorithms tailored for drug discovery and development. With over 70 years’ worth of development, it stands as one of the most advanced tools in identifying intricate relationships between potential drugs and diseases on a molecular scale. This platform accelerates the creation of innovative treatments, enabling pharmaceutical companies to bring solutions to market swiftly, particularly benefiting patients with rare diseases lacking adequate research. By synthesizing biomedical data from various sources such as literature, trials, and databases, Hyper-C provides structured insights essential for modeling disease processes and drug actions at the molecular level. Through network alignment algorithms, it pinpoints promising drug repositioning candidates by aligning drug mechanisms with disease pathophysiology.

The Advantages of AI and Hyper-C

Delta4’s methodology is data-driven, drawing from various sources such as scientific publications, clinical trial data, patents, and genetic databases. The integration of this diverse information enables them to conduct detailed network analyses, identifying promising disease models that align closely with Iguratimod’s molecular profile. The outcomes of Delta4’s computational drug repurposing efforts successfully identified three novel indications for Iguratimod - respiratory tract disease, urogenital disease, and an eye disease. These findings are supported by rigorous mechanistic analyses and AI-driven screening techniques, highlighting the efficacy and reliability of their approach. By using Hyper-C, Delta4 was able to reduce discovery and development time, increase their probability of success, increase drug discovery efficiency, provide a clear mechanism of action hypotheses and provide biomarker candidates for stratification.